Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with PKU
Synlogic, Inc., (Nasdaq: SYBX), a clinical stage company developing a novel class of Synthetic BioticTM therapeutics, announced positive top-line clinical data from patient cohorts of a randomized, double-blind, placebo-controlled Phase 1/2a study of SYNB1618, which […]